Intended for healthcare professionals

Rapid response to:

Feature

Covid-19: What next for the Valneva vaccine?

BMJ 2021; 375 doi: https://doi.org/10.1136/bmj.n2839 (Published 23 November 2021) Cite this as: BMJ 2021;375:n2839

Read our latest coverage of the coronavirus pandemic

Rapid Response:

Re: Covid-19: What next for the Valneva vaccine?

Dear Editor,

One wonders if the health secretary even considered that Valneva is whole virus vaccine, compared to other vaccines in use.
Early worries around Omicron variant are of potential to evade current vaccines. Was this potential not considered prior to cancelling the contract? Or have they just looked at how many total vaccines we have and the cost.

Regards

Competing interests: Sibling is participant in Valneva study (blinded to vaccine allocation)

28 November 2021
Tim Smith
Paediatrics specialty trainee
Manchester